Opendata, web and dolomites

ReGenHeart SIGNED

Clinical development and proof of principle testing of new regenerative VEGF-D therapy for cost-effective treatment of refractory anginaA phase II randomized, double-blinded, placebo-controlled study

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ReGenHeart project word cloud

Explore the words cloud of the ReGenHeart project. It provides you a very rough idea of what is the project "ReGenHeart" about.

pet    area    endpoints    suffer    multicentre    intramyocardial    catheter    levels    patient    substantial    service    dose    procedure    primary    blinded    months    chronic    mediated    burden    individual    suffers    annual    endpoint    follow    final    man    ready    debilitating    placebo    health    optimized    mri    regenheart    therapy    multiple    refractory    lt    life    feasibility    hospitalizations    either    proof    approval    patients    randomized    surgery    single    never    recruited    mace    efficient    score    quality    induce    mortality    12    imaging    heart    relatively    minutes    arms    unfortunately    medical    adenovegf       subgroup    class    reduce    gene    angiogenesis    180    safety    regulatory    walk    regenerative    percutaneous    six    double    therapeutic    clinical    preclinical    healthcare    extensive    trial    pectoris    benefits    validation    ccs    subject    centres    angina    conduct    disease    angioplasty   

Project "ReGenHeart" data sheet

The following table provides information about the project.

Coordinator
POHJOIS-SAVON SAIRAANHOITOPIIRIN KUNTAYHTYMA 

Organization address
address: PL 100
city: KYS
postcode: 70029
website: www.kuh.fi

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Finland [FI]
 Project website https://www.regenheart.eu/
 Total cost 5˙934˙088 €
 EC max contribution 5˙934˙086 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2016-RTD
 Funding Scheme RIA
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    POHJOIS-SAVON SAIRAANHOITOPIIRIN KUNTAYHTYMA FI (KYS) coordinator 1˙962˙787.00
2    MEDIZINISCHE UNIVERSITAET WIEN AT (WIEN) participant 621˙668.00
3    FINVECTOR OY FI (KUOPIO) participant 616˙967.00
4    QUEEN MARY UNIVERSITY OF LONDON UK (LONDON) participant 610˙260.00
5    SLASKI UNIWERSYTET MEDYCZNY W KATOWICACH PL (KATOWICE) participant 591˙250.00
6    REGION HOVEDSTADEN DK (HILLEROD) participant 564˙182.00
7    SERVICIO MADRILENO DE SALUD ES (MADRID) participant 523˙021.00
8    A2F ASSOCIATES LIMITED UK (NEWMARKET) participant 301˙870.00
9    UNIVERSITY COLLEGE LONDON UK (LONDON) participant 142˙081.00

Map

 Project objective

Chronic angina pectoris is a debilitating chronic disease, a subgroup of these patients suffers from refractory angina which unfortunately can’t be controlled by medical therapy (angioplasty or surgery). Refractory angina is a substantial burden on the individual and healthcare system, in Europe there are 100,000 new cases per year, annual mortality of these patients is relatively low (<4%) thus refractory angina patients suffer multiple hospitalizations and low levels of health-related quality of life.

The ReGenHeart project is based on extensive preclinical work and a phase I safety, feasibility and dose-finding clinical study recently completed by the consortium. The project will conduct a multicentre, randomized, placebo-controlled, double-blinded Phase II clinical study to provide proof of concept and clinical validation for a new, percutaneous, cost-efficient therapy for refractory angina patients. Using our optimized catheter-mediated intramyocardial approach with AdenoVEGF-D, which has never been used in man before our phase I trial, we aim to induce regenerative changes supported by therapeutic angiogenesis in the affected area of a patient's heart and, in a single procedure, reduce the burden on the individual and their health service.

The proposed trial is ready to proceed, subject to final regulatory approval in the six European clinical centres. 180 CCS class 2-3 refractory angina patients will be recruited, which will allow us to assess the benefits of therapy to patients who still have potential to respond to the regenerative therapy. Patients will be randomized 2:1 to either the gene therapy or placebo arms.

Trial follow up, at 6 and 12 months, will assess how far they can walk in 6 minutes (primary endpoint) and also by their CCS angina score, quality of life, so-called MACE endpoints and several advanced PET and MRI imaging endpoints.

 Deliverables

List of deliverables.
Project website Websites, patent fillings, videos etc. 2020-04-08 14:15:03

Take a look to the deliverables list in detail:  detailed list of ReGenHeart deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "REGENHEART" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "REGENHEART" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

DIAdIC (2019)

Evaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trial

Read More  

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More